首页 | 本学科首页   官方微博 | 高级检索  
检索        

恶性腹膜间皮瘤的诊疗现状及进展
引用本文:李娜,陈忠坚,毛伟敏.恶性腹膜间皮瘤的诊疗现状及进展[J].肿瘤防治研究,2020,47(12):992-995.
作者姓名:李娜  陈忠坚  毛伟敏
作者单位:310022 杭州,中国科学院大学附属肿瘤医院(浙江省肿瘤医院),中国科学院基础医学与肿瘤研究所
基金项目:国家自然科学基金(81672315)
摘    要:恶性腹膜间皮瘤是一种临床罕见,与石棉暴露密切相关的高侵袭性肿瘤。由于前期石棉材料的广泛应用,目前发病率呈明显上升趋势。该病起病隐匿,临床确诊时多为晚期,预后较差,中位生存期仅为12月。恶性腹膜间皮瘤治疗方法主要是肿瘤细胞减灭术联合腹腔热灌注化疗,目前多项免疫及分子靶向治疗正在研究中。本文就恶性腹膜间皮瘤的诊治现状作一综述,以期提高对该病的认识,进而为恶性腹膜间皮瘤的诊治提供参考。

关 键 词:恶性腹膜间皮瘤  诊断  治疗  
收稿时间:2020-04-20

Current Status and Progress on Diagnosis and Treatment of Malignant Peritoneal Mesothelioma
LI Na,CHEN Zhongjian,MAO Weimin.Current Status and Progress on Diagnosis and Treatment of Malignant Peritoneal Mesothelioma[J].Cancer Research on Prevention and Treatment,2020,47(12):992-995.
Authors:LI Na  CHEN Zhongjian  MAO Weimin
Institution:Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhengjiang Cancer Hospital), Hangzhou 310022, China
Abstract:Malignant peritoneal mesothelioma(MPM) is a rare and aggressive tumor and highly associated with asbestos exposure. Due to the wide application of asbestos materials in the early stage, the incidence of MPM is increasing now. The symptoms of MPM are atypical, so most of patients are in the late stage when diagnosed. And the prognosis is so poor that the median survival time is only 12 months. Now the main treatment of MPM is CRS-HIPEC, at the same time, a number of immune and targeted treatments are under study. This article reviews the current status of treatment on MPM, aiming to improve the understandings of this disease and provide a reference for the clinical diagnosis and treatment.
Keywords:Malignant peritoneal mesothelioma  Diagnosis  Therapy  
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号